This HTML5 document contains 86 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00374/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00374/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00374/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n21http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00374/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00374/identifier/wikipedia/
n16http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00374
rdf:type
n3:Drug
n3:description
Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®. [Wikipedia]
n3:dosage
n20:271B6371-363D-11E5-9242-09173F13E4C5 n20:271B6372-363D-11E5-9242-09173F13E4C5 n20:271B636D-363D-11E5-9242-09173F13E4C5 n20:271B636E-363D-11E5-9242-09173F13E4C5 n20:271B636F-363D-11E5-9242-09173F13E4C5 n20:271B6370-363D-11E5-9242-09173F13E4C5 n20:271B6369-363D-11E5-9242-09173F13E4C5 n20:271B636A-363D-11E5-9242-09173F13E4C5 n20:271B636B-363D-11E5-9242-09173F13E4C5 n20:271B636C-363D-11E5-9242-09173F13E4C5 n20:271B6366-363D-11E5-9242-09173F13E4C5 n20:271B6367-363D-11E5-9242-09173F13E4C5 n20:271B6368-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
n3:indication
For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
n3:manufacturer
n7:271B635E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00374 n23:DB00374
dcterms:title
Treprostinil
adms:identifier
n13:66302-206-01 n14:DB00374 n15:50861 n22:PA164768801 n24:Treprostinil
n3:mechanismOfAction
The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
n3:packager
n7:271B635C-363D-11E5-9242-09173F13E4C5 n7:271B635D-363D-11E5-9242-09173F13E4C5
n3:patent
n17:6521212 n17:5153222
n3:synonym
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid Treprostinil (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid Treprostinilo Uniprost Treprostinilum
n3:toxicity
Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
n3:volumeOfDistribution
* 14 L/70 kg
n10:hasAHFSCode
n11:24-12-92
n3:proteinBinding
Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.
n3:synthesisReference
Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh, "TREPROSTINIL PRODUCTION." U.S. Patent US20110319641, issued December 29, 2011.
foaf:page
n19:treprostinil-inhalation-solution.html n21:remodulin.htm
n3:IUPAC-Name
n4:271B6377-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B637D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B637C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6379-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B637A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B637B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B638D-363D-11E5-9242-09173F13E4C5 n4:271B6375-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B638E-363D-11E5-9242-09173F13E4C5 n4:271B6373-363D-11E5-9242-09173F13E4C5 n4:271B6376-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6374-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n16:B01AC21
n3:H-Bond-Acceptor-Count
n4:271B6383-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6384-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B637E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B637F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6381-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6380-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6382-363D-11E5-9242-09173F13E4C5
n3:absorption
Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
81846-19-7
n3:category
n3:containedIn
n5:271B6365-363D-11E5-9242-09173F13E4C5 n5:271B6363-363D-11E5-9242-09173F13E4C5 n5:271B6364-363D-11E5-9242-09173F13E4C5 n5:271B6361-363D-11E5-9242-09173F13E4C5 n5:271B6362-363D-11E5-9242-09173F13E4C5 n5:271B635F-363D-11E5-9242-09173F13E4C5 n5:271B6360-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6389-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B638B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B638C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6388-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6387-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B638A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6378-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6385-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6386-363D-11E5-9242-09173F13E4C5